Abstract This biographical sketch on John Albert Key corresponds to the historic text, The Classic: Sulfonamides in the Treatment of Chronic Osteomyelitis, available at
its president in 1945-6. However, the list of organizations in which he served is indeed long, He was also a prolific contributor to the literature in areas as diverse as tumors, trauma, infection, spine, degenerative and inflammatory conditions, including many experimental studies in animals, and had a commanding knowledge of those fields.
The article we highlight this month relates to the use of sulfonamides in osteomyelitis [3] . Various forms of sulfa drugs were introduced in the 1930s [6] . Interestingly, the first drug, Prontosil (Bayer Laboratories, Frankfurt, Germany), had no effect in the test tube, and a French team at the Pasteur Institute discovered in vivo the drug was metabolized into two portions, only one of which, sulfanilamide, was active. Hundreds of manufacturers subsequently produced various forms, one of which contained diethylene glycol, poisoning hundreds of people, and contributing to the enactment of the Federal Food, Drug, and Cosmetic Act in 1938. Key was one of the early investigators of sulfa drugs for musculoskeletal infections [4] , performing both experimental and clinical studies, and suggesting they might impair wound healing. In the article we reproduce here [3] , Key noted: ''…sulfonamides in the blood stream cannot exert their maximum effects upon bacteria in localized areas of disease…'' but ''…the systemic administration of sulfadiazine, and especially sulfathiazole, to patients with acute osteomyelitis or an acute exacerbation of chronic osteomyelitis, usually has a beneficial effect, not only upon the septicaemia, but also upon the local disease.'' Key emphasized the drugs were only an adjunct to appropriate surgery, and that local application was also helpful. He was careful to note the dangers of the drug, including local reactions to too much added sulfa. Even though a proponent of the Orr method of treatment (débridement and casting with repeat treatments as necessary, and leaving the wound to close by secondary intention), Key recognized sulfa drugs would allow the primary closing of many wounds and avoidance of a ''…longer interval (of treatment) and considerable unpleasantness.'' Dr. Key was a careful researcher, always cognizant of the potential downsides of treatment, but eager to explore new methods with proper experimental studies.
